Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease

Neurology

Volumn 54, Issue 7, 2000, Pages 1482-1487

  Kaasinen, Valtteri ^a   Nagren K ^b   Hietala, J ^a   Oikonen, V ^b   Vilkman, H ^a   Farde, L ^c   Halldin, C ^c   Rinne, J O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU PET CENTRE   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

D2 subtype; D3 subtype; Dopamine receptors; PD

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATHOGENESIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY;

EID: 17644438752     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.7.1482     Document Type: Article

References (52)

1. Rinne UK, Laihinen A, Rinne JO, Någren K, Bergman J, Ruotsalainen U. Positron emission tomography (PET) demonstrates dopamine D-2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
2. Rinne JO, Laihinen A, Någren K, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 1990;27:494-499.
3. 11C]raclopride. Neurology 1991; 41(suppl 1):211.
4. Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-138.
5. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projections in dopa-naïve parkinsonism. Brain 1993;116:853-867.
6. 11C]raclopride. J Neurol Sci 1995;132:156-161.
7. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49: 717-723.
8. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders 2. Cornwall, UK: Butterworth, 1987.
9. 3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome. J Neurol Sci 1979;43:429-437.
10. Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 1993;14:184-194.
11. Cortes R, Camps M, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D-1 and D-2 sites in Parkinson syndromes of different aetiology. Brain Res 1989;483:30-38.
12. Reisine TD, Fields JZ, Yamamura HI. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci 1977;21: 335-343.
13. Rinne UK, Koskinen V, Lönnberg P. Neurotransmitter receptors in the parkinsonian brain. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease - current progress, problems and management. Amsterdam: Elsevier, 1980:93-107.
14. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984;99:167-175.
15. Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996;46:791-795.
16. Ricci A, Bronzetti E, Mulatero P, Schena M, Veglio F, Amenta F. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives. Hypertension 1997;30:1566-1571.
17. 125I]epidepride. Brain Res 1993;609:237-243.
18. Halldin C, Farde L, Högberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995;36:1275-1281.
19. 11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 1997;133:396-404.
20. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
21. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97-113.
22. Schachter SC, Ransil BJ, Geschwind N. Associations of handedness with hair color and learning disabilities. Neuropsychologia 1987;25:269-276.
23. 11C]methyl triflate. Appl Radiat Isot 1992;43:1383-1385.
24. 11C]methionine. J Labelled Comp Radiopharm 1998;41:831-841.
25. 11C]methyl triflate. J Labelled Comp Radiopharm 1998;41: 545-556.
26. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
27. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 1996;43:2199-2206.
28. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999;19:1164-1173.
29. Pellizari CA, Chen GTY, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comp Assist Tomogr 1989; 13:20-26.
30. Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AK. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab 1991;11: 1-9.
31. Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11-labelled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54.
32. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52.
33. Knable MB, Jones DW, Coppola R, et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995;36:1216-1225.
34. 11C-raclopride and PET. Ann Neurol 1992;31:184-192.
35. Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998;13:788-797.
36. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347:146-151.
37. Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988;86:291-306.
38. Rinne JO, Laihinen A, Lönnberg P, Marjamäki P, Rinne UK. A postmortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122.
39. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60-80.
40. Dooley M, Markham A. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 1998;12:495-514.
41. 11C]Raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325-1329.
42. Herrero MT, Augood SJ, Asensi H, et al. Effects of L-DOPA therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Brain Res Mol Brain Res 1996;42:149-155.
43. Morissette M, Goulet M, Calon F, et al. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol Pharmacol 1996;50:1073-1079.
44. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci 1997; 94:3363-3367.
45. Tamaru F. Disturbances in higher function in Parkinson's disease. Eur Neurol 1997;38(suppl 2):33-36.
46. Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Ann NY Acad Sci 1988; 537:330-338.
47. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ. Depression in Parkinson's disease. A positron emission study. Br J Psychiatry 1994;165:333-339.
48. Grossman M, Crino P, Reivich M, Stern MB, Hurtig HI. Attention and sentence processing deficits in Parkinson's disease: the role of anterior cingulate cortex. Cereb Cortex 1992; 2:513-525.
49. Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994;36:230-236.
50. Farde L, Gustavsson JP, Jönsson E. D2 dopamine receptors and personality traits. Nature 1997;385:590.
51. Alexander GE, Delong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
52. Joyce JN, Goldsmith SG, Gurevich EV. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. J Psychiatr Res 1997;31:197-217.